Veradigm logo

Our unique real world data assets combined with our industry-leading research team are delivering rich, deep data, innovative research, and actionable real-world evidence solutions.  

Section 3 call out. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo.

Section 4 Header

Section 4 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Section 5 Header

Section 5 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Section 6 Header

Section 6 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

What can we do for you?

Complete this short form for a data feasibility assessment, or to talk to one of our experts about your real-world evidence generation needs. 

Section 8 Header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Section 8 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consecte-tur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo.

Section 9 Header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Section 9 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consecte-tur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo.

Section 10 header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Section 10 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consecte-tur adipiscing elit. Lorem ipsum dolor sit

Section 11 Header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Section 11 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consecte-tur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo.

Section 12 header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Section 12 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consecte-tur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo.

Identifying and addressing gaps in care

In a study conducted by scientists at Eli Lilly and Veradigm,1 unstructured qualitative provider notes recorded in electronic health records (EHRs) during visits with patients with atopic dermatitis (AD) were shown to rarely to document AD burden on daily functioning and quality of life.

The study demonstrates how combining defined data from EHR structured fields with NLP-extracted information from provider notes captured in unstructured fields offers potential to broaden understanding of AD impact and management.

Safety and effectiveness studies

In a study conducted by Seqirus and Veradigm and published in Clinical Infectious Diseases,3 individuals four years and older who were vaccinated with cell culture-derived inactivated quadrivalent influenza vaccine (ccIIV4) had significantly fewer influenza-related medical encounters compared with individuals vaccinated with egg-derived inactivated quadrivalent influenza vaccines (eIIV4) during the 2018-19 flu season in the United States.

Study findings “provide further evidence supporting [cell-derived] ccIIV4 as a potentially more effective public health measure against influenza than an egg-derived equivalent.”

Retrospective studies 

This retrospective cohort study, conducted by researchers from AstraZeneca and Veradigm, used data sourced from a nationwide, electronic health record platform, linked to transactional administrative claims.2

The study provides the first comprehensive evaluation of blood eosinophil count, healthcare utilization, and cost as reflected in current clinical practice across the United States.

Clinical characteristics & healthcare resource use

Early real-world use of erenumab was associated with high adherence and reductions in previously used acute and preventive medications, according to a study conducted by investigators at Amgen and Veradigm and published in Cephalalgia Reports.4

To date, the study is the largest to describe characteristics and treatment patterns of patients who initiated erenumab in US routine clinical practice.

Section 17 header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Column 1 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 1 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 2 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 2 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Section 18 header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Column 1 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 1 text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 2 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 2 text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Section 19 header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Column 1 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 1 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 2 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 2 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 3 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 3 body. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

section 20 header. Lorem ipsum dolor sit cmet, consectetur adipiscing elit.

Column 1 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 1 text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 1 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 1 text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 1 header. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Column 1 text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas porta commodo ipsum eget cursus. Morbi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Linked data: the new research standard

While administrative claims data continues to be a trusted workhorse, new linkages to deep, clinical data give traditional real-world data a much-needed boost in horsepower. Claims data linked to electronic health record (EHR) data provides the best of all worlds: deep, rich clinical insights documented in the patient record, linked to detailed information about all costs and services found in claims data.

As one of the largest providers of deidentified ambulatory EHR data that is captured and curated directly from our own point of care systems, we provide flexible linked data solutions supporting multiple claims data providers and linking technologies. Veradigm offers both off-the-shelf and custom linked data solutions that meet your research needs.

Industry veterans driving innovative solutions

Veradigm’s research team is well-regarded throughout the industry, with decades of real-world evidence generation experience from a variety of backgrounds. When our expertise is combined with Veradigm’s linked data assets and point-of-care platforms we are able to drive new, innovative solutions. Take a look at a few of our notable case studies below to see how our data and expertise have combined to delight our clients and advance scientific knowledge. 

Our high-quality linked database set includes:

Notable case studies
Section Head 2
Section Head 3

1. Pierce EJ, Boytsov NN, Vasey JJ, et al. A qualitative analysis of provider notes of atopic dermatitis-related visits using natural language processing methods. Dermatol Ther (Heidelb) 30 May 2021; https://doi.org/10.1007/s13555-021-00553-5

2. Trudo F, Kallenbach L, Vasey J, et al. Clinical and economic burden of eosinophilic COPD in a large retrospective US cohort. Int J Chronic Ob Pulmonary Dis 2019:14:2625-2637. doi:10.2147COPD.S220009.

3. Boikos C, Fischer L, O’Brien D, et al. Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States. Clin Infect Dis 2021;ciaa1944. https://pubmed.ncbi.nlm.nih.gov/33400775/

4. Bogdanov A, Chia V, Bensink M, et al. Early use of erenumab in US real world practice. Cephalalgia Rep 31 May 2021;4. https://doi.org/10.1177/25158163211020419

What can we do for you?
Contact us for a feasibility consultation.